Cheng Yi Pharma(SH:603811) Xin Lang Cai Jing·2025-12-28 12:33Group 1 - The core focus of the news is the establishment of the "Biopharmaceutical Innovation Alliance" in Qiantang District, aimed at addressing challenges in the biopharmaceutical industry such as long R&D cycles and complex intellectual property layouts [1][2] - Qiantang District has developed into a mature ecosystem for biopharmaceutical innovation, with over 1,800 companies in Hangzhou Medical Port, including 7 of the top 10 global pharmaceutical companies and 35 "quasi-unicorn" enterprises [2][3] - The alliance's theme is "AI + Biopharmaceuticals," aligning with national strategies in pharmaceutical technology, and aims to create a tighter collaboration network among industry, academia, and research [2][3] Group 2 - The biopharmaceutical industry in Qiantang has a revenue exceeding 50 billion yuan, supported by a 500 billion yuan industrial fund matrix to provide financial backing throughout the lifecycle of enterprises [3] - The region has established a preliminary industrial closed loop in the "AI + Biopharmaceutical" field, including AI target discovery, automated experiments, and digital clinical trials [2][3] - Qiantang District aims to achieve a biopharmaceutical industry scale exceeding 100 billion yuan by 2028, with a focus on collaboration among universities, platforms, enterprises, and the industry chain [3]